Opioid agonist and antagonist activities of peripherally selective derivatives of naltrexamine and oxymorphamine
- 1 September 1989
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 32 (9) , 2068-2071
- https://doi.org/10.1021/jm00129a009
Abstract
A series of .beta.-naltrexamine and .beta. oxymorphamine derivatives that contain ionizable moieties coupled to the 6.beta.-amino group were synthesized in an effort to develop antagonists and agonists that have negligible access into the central nervous system (CNS). Among the .beta.-naltrexamine derivatives 1-7, all displayed partial agonism on the guinea pig ileal longitudinal muscle preparation except for aspartyl derivative 6, which was a full agonist with activity in the range of morphine. The .beta.-oxymorphamine derivatives 8-12 were all full agonists with potencies ranging from 1.5 to 6.1 times that of morphine. Among the compounds evaluated in mice for antinociceptive or opioid antagonist activities, aspartyl derivative 6 possessed the greatest difference between peripheral (po or iv) and icv equiactive antagonist doses. Compared to naltrexone, 6 was > 100 times more potent by the icv route, but 6000-10000 times less potent when administered po or icv. The present study suggests that zwitterionic groups are highly effective in preventing penetration of ligands into the CNS. Such ligands may be useful pharmacologic tools for investigation of peripheral opioid mechanisms. Moreover, they could find clinical applications when the central actions are unwanted.This publication has 10 references indexed in Scilit:
- Irreversible blockage of opioid receptor types by ester homologs of .beta.-funaltrexamineJournal of Medicinal Chemistry, 1986
- Activity of N-methyl-.alpha.- and -.beta.-funaltrexamine at opioid receptorsJournal of Medicinal Chemistry, 1986
- Design and synthesis of naltrexone-derived affinity labels with nonequilibrium opioid agonist and antagonist activities. Evidence for the existence of different .mu. receptor subtypes in different tissuesJournal of Medicinal Chemistry, 1984
- Comparative antagonism by naltrexone and naloxone of μ, κ, and δ agonistsEuropean Journal of Pharmacology, 1984
- INVIVO STUDIES ON SPINAL OPIATE RECEPTOR SYSTEMS MEDIATING ANTINOCICEPTION .2. PHARMACOLOGICAL PROFILES SUGGESTING A DIFFERENTIAL ASSOCIATION OF MU-RECEPTOR, DELTA-RECEPTOR AND KAPPA-RECEPTOR WITH VISCERAL CHEMICAL AND CUTANEOUS THERMAL STIMULI IN THE RAT1984
- Receptor binding, antagonist, and withdrawal precipitating properties of opiate antagonistsLife Sciences, 1983
- U-50,488 - A SELECTIVE AND STRUCTURALLY NOVEL NON-MU-(KAPPA)-OPIOID AGONIST1983
- RELATIVE INVOLVEMENT OF MU, KAPPA AND DELTA-RECEPTOR MECHANISMS IN OPIATE-MEDIATED ANTINOCICEPTION IN MICE1983
- The possible role of intracellular receptors in the expression of narcotic antagonist precipitated abstinenceLife Sciences, 1981
- STIMULANT ACTIONS OF VOLATILE ANAESTHETICS ON SMOOTH MUSCLEBritish Journal of Pharmacology and Chemotherapy, 1964